Arndt Vogel,ย Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Cristina Smolenschi,ย et al. on X:
“Real-world efficacy of zanidatamab in HER2 positive advanced biliary tract cancers.
- RWD.
- ORR 40%, DCR 65%.
- mPFS 6.7mo, 1-yr OS 80%.
- Higher efficacy in 3+ vs 2+.
- Confirmed benefit for Zanidatamab.”
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers.
Authors: Cristinaย Smolenschi,ย et al.
